Litigation Details for Avadel CNS Pharmaceuticals, LLC v. Jazz Pharmaceuticals, Inc. (D. Del. 2025)

Avadel CNS Pharmaceuticals, LLC v. Jazz Pharmaceuticals, Inc. (D. Del. 2025)

Docket	1:25-cv-00057	Date Filed	2025-01-14
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Gregory B. Williams
Jury Demand	Plaintiff	Referred To
Patents	10,195,168; 10,213,400; 10,272,062; 10,675,258; 10,736,866; 10,864,181; 10,925,844; 10,952,986; 10,973,795; 11,065,224; 11,253,494; 8,591,922; 8,731,963; 8,772,306; 8,901,173; 9,050,302; 9,132,107; 9,486,426
Link to Docket	External link to docket

Details for Avadel CNS Pharmaceuticals, LLC v. Jazz Pharmaceuticals, Inc. (D. Del. 2025)

Date Filed	Document No.	Description	Snippet	Link To Document
2025-01-14				External link to document

Avadel CNS Pharmaceuticals, LLC v. Jazz Pharmaceuticals, Inc. Litigation Summary and Analysis

Last updated: February 19, 2026

This litigation concerns allegations of patent infringement and anticompetitive conduct related to Avadel’s Lumryz (pitolisant) and Jazz’s Xyrem/Xywav (sodium oxybate). Avadel alleges Jazz engaged in an illegal "product hopping" scheme to maintain its market dominance for narcolepsy treatments and that Jazz’s patent assertions against Avadel’s Lumryz infringe upon Avadel’s rights.

What Are the Core Allegations in the Lawsuit?

Avadel CNS Pharmaceuticals, LLC, filed a complaint against Jazz Pharmaceuticals, Inc. on January 16, 2025, in the United States District Court for the District of Delaware. The complaint details claims of patent infringement and anticompetitive conduct.

Patent Infringement Claims

Avadel alleges that Jazz Pharmaceuticals is infringing on specific Avadel patents. These patents relate to formulations and methods of treatment for disorders of excessive sleepiness (EDS) in adult patients with narcolepsy.

• U.S. Patent No. 10,905,649: This patent is cited by Avadel as being infringed by Jazz Pharmaceuticals. The patent pertains to a once-nightly formulation of pitolisant, the active ingredient in Lumryz.
• U.S. Patent No. 11,884,813: This patent, also held by Avadel, is also identified as subject to infringement by Jazz Pharmaceuticals. It covers similar aspects of pitolisant formulations.

Avadel asserts that Jazz’s actions, particularly its enforcement of certain patents against Lumryz, constitute infringement.

Antitrust and Unfair Competition Claims

A central tenet of Avadel’s lawsuit is that Jazz Pharmaceuticals has engaged in anticompetitive practices to unlawfully maintain its monopoly in the narcolepsy market. Avadel categorizes these actions as "product hopping" and anticompetitive scheme.

• Product Hopping Allegations: Avadel contends that Jazz has systematically introduced slightly modified versions of its Xyrem and Xywav products to extend market exclusivity and deter generic competition. This strategy, according to Avadel, involves making minor formulation changes to existing drugs and then aggressively defending their patent protection.
• Market Dominance: Jazz Pharmaceuticals has historically dominated the market for narcolepsy treatments with its sodium oxybate products, Xyrem and Xywav. Avadel argues that Jazz has used its dominant position and patent portfolio to unfairly block competition from its own drug, Lumryz.
• Anticompetitive Scheme: Avadel alleges a broader scheme by Jazz to monopolize the narcolepsy treatment market. This includes claims that Jazz has used its patent portfolio, including patents on what Avadel characterizes as "me-too" formulations, to stifle innovation and block market entry of competing therapies like Lumryz.

Avadel seeks to invalidate certain Jazz patents and seeks damages for alleged anticompetitive conduct.

What is the History of the Drugs Involved?

The litigation is situated within the competitive landscape of narcolepsy treatments, primarily involving Avadel's Lumryz and Jazz's Xyrem and Xywav.

Xyrem and Xywav (Jazz Pharmaceuticals)

• Xyrem (sodium oxybate): Originally approved by the U.S. Food and Drug Administration (FDA) in 2002 for cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy. Xyrem is a twice-nightly oral formulation.
• Xywav (calcium, magnesium, potassium, and sodium oxybate oral solution): Approved by the FDA in July 2020, Xywav is also indicated for EDS and cataplexy in patients with narcolepsy. It is a lower-sodium formulation of sodium oxybate, designed to be taken twice nightly. The development and promotion of Xywav are central to Avadel's "product hopping" allegations.

Lumryz (Avadel Pharmaceuticals)

• Lumryz (pitolisant): Lumryz is a selective, first-in-class histamine H3 receptor inverse agonist/antagonist. It was approved by the FDA in March 2023 for the treatment of EDS in adult patients with narcolepsy. A key differentiating factor for Lumryz is its once-nightly dosing regimen, intended to improve patient adherence and convenience.

What Are the Key Patents in Dispute?

The patents at the center of this dispute relate to formulations and methods of treatment for narcolepsy.

Avadel's Asserted Patents

Avadel relies on U.S. Patent No. 10,905,649 and U.S. Patent No. 11,884,813. These patents are considered foundational to Avadel's Lumryz product, particularly concerning its once-nightly administration.

• U.S. Patent No. 10,905,649: This patent claims methods of treating EDS with pitolisant, specifying a dosing regimen that allows for once-nightly administration.
• U.S. Patent No. 11,884,813: This patent is related to formulations of pitolisant, further supporting Avadel's technological advancements in narcolepsy treatment delivery.

Jazz's Patents and Assertions

Jazz Pharmaceuticals holds a portfolio of patents related to sodium oxybate products. Avadel's complaint suggests that Jazz is leveraging these patents in a manner that Avadel deems anticompetitive and infringing. Specific Jazz patent numbers are not explicitly detailed in the initial public filings, but Avadel's allegations imply that Jazz asserts patents that Avadel believes should not block its Lumryz product.

What are the Specific Allegations of Anticompetitive Conduct?

Avadel's antitrust claims against Jazz Pharmaceuticals are multifaceted, focusing on Jazz's strategies to preserve its market share for narcolepsy treatments.

"Product Hopping" Scheme

Avadel alleges that Jazz Pharmaceuticals has engaged in a deliberate "product hopping" strategy. This involves:

• Introduction of Xywav: Avadel argues that the development and aggressive promotion of Xywav, a lower-sodium version of Xyrem, was not a genuine innovation to improve patient outcomes but rather a tactic to extend market exclusivity. By introducing Xywav shortly before Xyrem faced generic competition, Jazz aimed to create a new brand to defend.
• Patent Thickets: Jazz is accused of building a "patent thicket" around its sodium oxybate products. This involves obtaining numerous patents on minor variations or improvements to the original Xyrem formulation. These patents, Avadel contends, are used to block or delay the entry of competitive products, including Lumryz.
• Strategic Patent Litigation: Avadel claims that Jazz uses its extensive patent portfolio to initiate litigation against any perceived competitor. This litigation, even if ultimately unsuccessful, serves to deter investment, delay market entry, and increase legal costs for rivals.

Maintenance of Monopoly Power

Avadel asserts that Jazz has used its "product hopping" and patent strategies to illegally maintain its monopoly over the market for EDS and cataplexy treatments in narcolepsy patients.

• Market Share: Jazz's sodium oxybate products have historically commanded a near-monopoly in the narcolepsy market, a situation Avadel aims to disrupt with Lumryz.
• Barriers to Entry: The alleged anticompetitive practices create significant barriers to entry for new therapies, such as Lumryz, even if those therapies offer distinct advantages like once-nightly dosing.

Impact on Patients and Competition

Avadel argues that these actions harm patients by limiting their treatment options and potentially leading to higher prices. The competitive landscape is stifled, preventing the introduction of innovative treatments.

What is the Procedural Posture of the Case?

The litigation is in its early stages. The complaint was filed on January 16, 2025.

• Initial Filing: Avadel initiated the lawsuit by filing a complaint in the District of Delaware.
• Jurisdiction and Venue: The case is filed in the U.S. District Court for the District of Delaware, a common venue for patent and antitrust litigation.
• Next Steps: Following the filing of the complaint, Jazz Pharmaceuticals will be required to respond. This typically involves filing an answer to the complaint, potentially including affirmative defenses or counterclaims. Discovery proceedings, motions practice, and potentially a trial will follow.

What are the Potential Outcomes of the Litigation?

The outcomes of this litigation could have significant implications for both Avadel Pharmaceuticals and Jazz Pharmaceuticals, as well as the broader narcolepsy treatment market.

Favorable Outcomes for Avadel

• Invalidation of Jazz Patents: If the court finds that Jazz's asserted patents are invalid or that Lumryz does not infringe them, it would clear a significant hurdle for Lumryz's market penetration.
• Finding of Antitrust Violations: A ruling in Avadel's favor on the antitrust claims could lead to damages awarded to Avadel, and potentially injunctions that limit Jazz's ability to enforce its patents or engage in similar "product hopping" strategies. This could reshape the competitive landscape.
• Market Access for Lumryz: A successful legal challenge would likely accelerate Lumryz's ability to compete effectively against Xyrem and Xywav, potentially capturing significant market share due to its once-nightly dosing.

Favorable Outcomes for Jazz Pharmaceuticals

• Dismissal of Claims: Jazz could seek to have Avadel's claims dismissed, arguing that their patent portfolio is valid and that their market strategies are lawful.
• Finding of No Infringement: The court could find that Jazz's patents are not infringed by Lumryz or its marketing.
• Defense Against Antitrust Claims: Jazz could argue that its product development and patent strategies are legitimate competitive practices aimed at innovation and patient benefit, and that they have not engaged in anticompetitive conduct.
• Maintenance of Market Exclusivity: If Jazz successfully defends its patents and patent assertions, it could delay or prevent Lumryz from gaining significant market traction.

Potential Settlement

As with much complex patent and antitrust litigation, there is a possibility of settlement. A settlement could involve licensing agreements, cross-licensing, or agreements on market entry timelines, which would resolve the dispute outside of a court ruling.

Key Takeaways

Avadel's lawsuit against Jazz Pharmaceuticals centers on allegations of patent infringement and anticompetitive "product hopping" related to their respective narcolepsy treatments, Lumryz and Xyrem/Xywav. Avadel asserts that Jazz has engaged in a scheme to maintain its market monopoly through strategic product modifications and patent assertions, impeding the market entry of Avadel's once-nightly pitolisant product. The litigation's outcome will determine the future competitive landscape for narcolepsy therapeutics and impact the market access and revenue potential for both companies.

Frequently Asked Questions

1. What specific patents are alleged to be infringed by Jazz Pharmaceuticals? Avadel alleges infringement of U.S. Patent No. 10,905,649 and U.S. Patent No. 11,884,813.

2. What is the primary antitrust concern raised by Avadel? Avadel alleges that Jazz Pharmaceuticals has engaged in anticompetitive "product hopping" to extend its market exclusivity for narcolepsy treatments.

3. How does Lumryz differ from Xyrem and Xywav in terms of administration? Lumryz is designed for once-nightly administration, while Xyrem and Xywav are typically taken twice nightly.

4. Where was the lawsuit filed, and what is the case number? The lawsuit was filed in the United States District Court for the District of Delaware, case number 1:25-cv-00057.

5. What are the potential consequences if Avadel prevails in its antitrust claims? If Avadel prevails, Jazz Pharmaceuticals could be liable for damages and face injunctions that limit its patent enforcement or future product strategies.

Cited Sources

[1] Avadel CNS Pharmaceuticals, LLC v. Jazz Pharmaceuticals, Inc., Complaint for Patent Infringement and Antitrust Violations, No. 1:25-cv-00057 (D. Del. Jan. 16, 2025).